Related Experiment Video
Updated: Aug 7, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis
Judit Ribas1, Jacint Boix, Laurent Meijer
1CNRS, Cell Cycle Group, Station Biologique, B.P. 74, 29682 Roscoff cedex, Bretagne, France.
Abstract:
In this study, we have analyzed the consequences, on several neuroblastoma cell lines, of combined treatments with (R)-roscovitine (CYC202, Seliciclib), a CDK inhibitory drug, and nutlin-3, a p53 activating drug. Both compounds were found to synergize, causing significant levels of apoptosis in cultured cells when combined at sublethal concentrations. In SH-SY5Y cells, Bcl-XL protein overexpression protected from apoptosis induced by either nutlin-3 alone or the (R)-roscovitine plus nutlin-3 association but failed to prevent apoptosis triggered by (R)-roscovitine alone. Moreover, Western blot studies showed that (R)-roscovitine increased nutlin-3-mediated p53 stabilization. Therefore, we conclude the contribution of (R)-roscovitine to the synergism is basically the sensitization of SH-SY5Y cells to the action of nutlin-3 on p53. The relevance of this pharmacological synergism with respect to the treatment of neuroblastoma is discussed.
Insights
Combining (R)-roscovitine and nutlin-3 synergistically induces apoptosis in neuroblastoma cells. (R)-roscovitine sensitizes cells to nutlin-3 by enhancing p53 stabilization, a key factor in this drug combination therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Neuroblastoma is a pediatric cancer with limited treatment options.
- Targeting cell cycle regulators and tumor suppressor pathways offers therapeutic potential.
Purpose of the Study:
- To investigate the synergistic effects of (R)-roscovitine and nutlin-3 on neuroblastoma cell lines.
- To elucidate the underlying molecular mechanisms of this drug combination.
Main Methods:
- Treatment of neuroblastoma cell lines (SH-SY5Y) with (R)-roscovitine and nutlin-3.
- Assessment of apoptosis levels and protein expression (Bcl-XL, p53) via Western blot.
Main Results:
- Combined (R)-roscovitine and nutlin-3 induced significant apoptosis at sublethal concentrations.
- Bcl-XL overexpression partially protected against apoptosis, but not from (R)-roscovitine alone.
- (R)-roscovitine enhanced nutlin-3-mediated p53 stabilization.
Conclusions:
- The combination therapy exhibits synergistic anti-cancer effects in neuroblastoma.
- (R)-roscovitine sensitizes cells to nutlin-3 by promoting p53 stabilization.
- This synergistic interaction holds promise for neuroblastoma treatment strategies.